Optimer Pharmaceuticals, Inc. | ||||
Consolidated Statements of Operations | ||||
(unaudited) | ||||
Three Months Ended | ||||
March 31, | ||||
2011 | 2010 | |||
Revenues: | ||||
Licensing | $ 69,165,000 | $ - | ||
Research grants | 111,639 | 297,437 | ||
Total revenues | 69,276,639 | 297,437 | ||
Cost and expenses: | ||||
Cost of licensing | 4,273,532 | - | ||
Research and development | 8,470,509 | 11,361,579 | ||
Marketing | 3,433,593 | 268,594 | ||
General and administrative | 8,280,182 | 2,388,712 | ||
Total operating expenses | 24,457,816 | 14,018,885 | ||
Income (loss) from operations | 44,818,823 | (13,721,448) | ||
Interest income and other, net | 23,242 | 24,778 | ||
Consolidated net income (loss) | $ 44,842,065 | $ (13,696,670) | ||
Net loss attributable to noncontrolling interest | 290,805 | 200,915 | ||
Net income (loss) attributable to Optimer Pharmaceuticals, Inc. | $ 45,132,870 | $ (13,495,755) | ||
Net income (loss) per share - basic | $ 1.06 | $ (0.39) | ||
Net income (loss) per share - diluted | $ 1.04 | $ (0.39) | ||
Weighted average number of shares used to compute net | ||||
income (loss) per share - basic | 42,661,533 | 35,001,596 | ||
Weighted average number of shares used to compute net | ||||
income (loss) per share - diluted | 43,399,798 | 35,001,596 | ||
Optimer Pharmaceuticals, Inc. | ||||
Condensed Consolidated Balance Sheets | ||||
March 31, | December 31, | |||
2011 | 2010 | |||
(unaudited) | ||||
ASSETS | ||||
Current assets: | ||||
Cash and cash equivalents | $ 139,687,802 | $ 19,861,924 | ||
Short-term investments | 40,408,051 | 29,553,506 | ||
Prepaid expenses and other current assets | 2,630,038 | 516,859 | ||
Total current assets | 182,725,891 | 49,932,289 | ||
Property and equipment, net | 863,980 | 697,683 | ||
Long-term investments | 882,000 | 882,000 | ||
Other assets | 791,857 | 508,190 | ||
Total assets | $ 185,263,728 | $ 52,020,162 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
Current liabilities: | ||||
Accounts payable | $ 5,168,991 | $ 2,307,820 | ||
Accrued expenses | 3,126,189 | 2,385,046 | ||
Total current liabilities | 8,295,180 | 4,692,866 | ||
Deferred rent | 134,239 | 141,138 | ||
Commitments and contingencies | - | - | ||
Stockholders’ equity | 176,834,309 | 47,186,158 | ||
Total liabilities and stockholders’ equity | $ 185,263,728 | $ 52,020,162 | ||
